Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Abstract 4128: Niraparib shows superior tissue distribution and efficacy in a prostate bone metastasis model compared with other PARP inhibitors

Linda A. Snyder, Rajendra N. Damle, Shefali Patel, Jared Bohrer, Jenny Driscoll, Rebecca Hawkins, Christopher F. Stratton, Carol Manning, Kanaka Tatikola, Volha Tryputsen, Kathryn Packman, Rao Mamidi

Cancer Res (2020) 80 (16_Supplement): 4128.

https://doi.org/10.1158/1538-7445.AM2020-4128

Published: 15 August 2020

View articletitled, Abstract 4128: Niraparib shows superior tissue distribution and efficacy in a prostate bone metastasis model compared with other PARP inhibitors

Journal Articles

Abstract 4127: Niraparib is active against prostate xenograft models that are wild type or defective for DNA damage repair genes

Linda A. Snyder, Krista Menard, Georges Habineza Ndikuyeze, Holly M. Nguyen, Anna Hughes, Lorraine Angelillo, Gerald Chu, Jenny Driscoll, Rebecca Hawkins, Eva Corey

Cancer Res (2020) 80 (16_Supplement): 4127.

https://doi.org/10.1158/1538-7445.AM2020-4127

Published: 15 August 2020

View articletitled, Abstract 4127: Niraparib is active against prostate xenograft models that are wild type or defective for DNA damage repair genes

Journal Articles

Abstract 2134: Niraparib combined with abiraterone acetate inhibits the growth of BRCA2^wt prostate tumors

Rajendra N. Damle, Rebecca Hawkins, Jennifer Hosbach, Georges Habineza Ndikuyeze, Jenny Driscoll, Natalie L. Fulton, David Derosa, Anna Hughes, Gerald Chu, Karl Calara-Nielsen, Denis Smirnov, Dong Shen, Linda A. Snyder

Cancer Res (2019) 79 (13_Supplement): 2134.

https://doi.org/10.1158/1538-7445.AM2019-2134

Published: 01 July 2019

View articletitled, Abstract 2134: Niraparib combined with abiraterone acetate inhibits the growth of BRCA2wt prostate tumors

Journal Articles

Abstract 2085: Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize tumor killing effect of an anti-VISTA monoclonal antibody in tumor bearing mice

Xiling Jiang, Jocelyn Leu, Indrajeet Singh, Linda A. Snyder, Weirong Wang

Cancer Res (2016) 76 (14_Supplement): 2085.

https://doi.org/10.1158/1538-7445.AM2016-2085

Published: 15 July 2016

View articletitled, Abstract 2085: Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize tumor killing effect of an anti-VISTA monoclonal antibody in tumor bearing mice

Journal Articles

Abstract PR07: Characterization of human effectors in the tumor microenvironment of NSCLC patients and lung tumor xenograft models

Hyun-Jeong Ra, Gisela Brake-Silla, Evgeniy Eruslanov, Michael Sharp, Charuhas Deshpande, Michael D. Feldman, Amy Ziober, Li-Ping Wang, Manuel A. Sepulveda, Linda A. Snyder, Gwenn Danet-Desnoyers

Cancer Res (2016) 76 (3_Supplement): PR07.

https://doi.org/10.1158/1538-7445.FBCR15-PR07

Published: 07 April 2016

View articletitled, Abstract PR07: Characterization of human effectors in the tumor microenvironment of NSCLC patients and lung tumor xenograft models

Journal Articles

Abstract 4011: Single cell transcriptomic analysis identified a potential dormant signature in prostate cancer disseminated tumor cells

Hung-Ming Lam, Lisly Chéry, Ilsa Coleman, Bryce Lakely, Sandy Larson, Roger Coleman, Julio Aguirre-Ghiso, Jing Xia, Roman Gulati, Peter S. Nelson, Bruce Montgomery, Paul H. Lange, Linda A. Snyder, Robert L. Vessella, Colm Morrissey

Cancer Res (2014) 74 (19_Supplement): 4011.

https://doi.org/10.1158/1538-7445.AM2014-4011

Published: 01 October 2014

View articletitled, Abstract 4011: Single cell transcriptomic analysis identified a potential dormant signature in prostate cancer disseminated tumor cells

Journal Articles

Cyclophosphamide Creates a Receptive Microenvironment for Prostate Cancer Skeletal Metastasis

Serk In Park, Jinhui Liao, Janice E. Berry, Xin Li, Amy J. Koh, Megan E. Michalski, Matthew R. Eber, Fabiana N. Soki, David Sadler, Sudha Sud, Sandra Tisdelle, Stephanie D. Daignault, Jeffrey A. Nemeth, Linda A. Snyder, Thomas J. Wronski, Kenneth J. Pienta, Laurie K. McCauley

Cancer Res (2012) 72 (10): 2522–2532.

https://doi.org/10.1158/0008-5472.CAN-11-2928

Published: 14 May 2012

View articletitled, Cyclophosphamide Creates a Receptive Microenvironment for Prostate Cancer Skeletal Metastasis

Includes: Supplementary data

Journal Articles

Abstract 817: Enhancement of paclitaxel and carboplatin therapy by CCL2 blockade in ovarian cancers

Francois Moisan, Edgar B. Francisco, Anamaria Brozovic, George E. Duran, Yan C. Wang, Shobha Seetharam, Linda A. Snyder, Parul Doshi, Branimir I. Sikic

Cancer Res (2012) 72 (8_Supplement): 817.

https://doi.org/10.1158/1538-7445.AM2012-817

Published: 15 April 2012

View articletitled, Abstract 817: Enhancement of paclitaxel and carboplatin therapy by CCL2 blockade in ovarian cancers

Journal Articles

Abstract 2842: CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis

Binzhi Qian, Jiufeng Li, Hui Zhang, Jinghang Zhang, Linda A. Snyder, Jeffrey W. Pollard

Cancer Res (2011) 71 (8_Supplement): 2842.

https://doi.org/10.1158/1538-7445.AM2011-2842

Published: 15 April 2011

View articletitled, Abstract 2842: CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis

Journal Articles

CCL2 Blockade Augments Cancer Immunotherapy

Zvi G. Fridlender, George Buchlis, Veena Kapoor, Guanjun Cheng, Jing Sun, Sunil Singhal, M. Cecilia Crisanti, Liang-Chuan S. Wang, Daniel Heitjan, Linda A. Snyder, Steven M. Albelda

Cancer Res (2010) 70 (1): 109–118.

https://doi.org/10.1158/0008-5472.CAN-09-2326

Published: 04 January 2010

View articletitled, CCL2 Blockade Augments Cancer Immunotherapy

Includes: Supplementary data

Journal Articles

A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone

Xin Li, Robert Loberg, Jinhui Liao, Chi Ying, Linda A. Snyder, Kenneth J. Pienta, Laurie K. McCauley

Cancer Res (2009) 69 (4): 1685–1692.

https://doi.org/10.1158/0008-5472.CAN-08-2164

Published: 12 February 2009

View articletitled, A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone

Includes: Supplementary data

Journal Articles

Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo

Robert D. Loberg, Chi Ying, Matt Craig, Lashon L. Day, Erin Sargent, Chris Neeley, Kirk Wojno, Linda A. Snyder, Li Yan, Kenneth J. Pienta

Cancer Res (2007) 67 (19): 9417–9424.

https://doi.org/10.1158/0008-5472.CAN-07-1286

Published: 01 October 2007

View articletitled, Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 4128: Niraparib shows superior tissue distribution and efficacy in a prostate bone metastasis model compared with other PARP inhibitors

Abstract 4127: Niraparib is active against prostate xenograft models that are wild type or defective for DNA damage repair genes

Abstract 2134: Niraparib combined with abiraterone acetate inhibits the growth of BRCA2^wt prostate tumors

Abstract 2085: Development of a mechanism-based pharmacokinetic/pharmacodynamic model to characterize tumor killing effect of an anti-VISTA monoclonal antibody in tumor bearing mice

Abstract PR07: Characterization of human effectors in the tumor microenvironment of NSCLC patients and lung tumor xenograft models

Abstract 4011: Single cell transcriptomic analysis identified a potential dormant signature in prostate cancer disseminated tumor cells

Cyclophosphamide Creates a Receptive Microenvironment for Prostate Cancer Skeletal Metastasis

Abstract 817: Enhancement of paclitaxel and carboplatin therapy by CCL2 blockade in ovarian cancers

Abstract 2842: CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis

CCL2 Blockade Augments Cancer Immunotherapy

A Destructive Cascade Mediated by CCL2 Facilitates Prostate Cancer Growth in Bone

Targeting CCL2 with Systemic Delivery of Neutralizing Antibodies Induces Prostate Cancer Tumor Regression In vivo

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only